Mr. Bleakley is a Director in Houlihan Lokey’s Business Services Group, covering pharma services and commercialization. He performs sellside and buyside M&A advisory engagements. Mr. Bleakley is based in the firm’s New York office.
Mr. Bleakley’s notable recent transactions include advising Varsity Healthcare Partners on its investment in Beghou Consulting; Spectrum Science on its investment from Knox Lane; OPEN Health on its acquisition of The CM Group; RevHealth on its sale to WindRose Health Investors; OPEN Health on its sale to Astorg; Fishawack Health on its acquisition of Avalere Health; Apollo Intelligence on its sale to Frazier Healthcare Partners; Random42 on its sale to The Lockwood Group; Novo Holdings on its acquisition of Medical Knowledge Group; Intouch Group on its sale to Eversana; The Lockwood Group on its investment from Ares; ClearView Healthcare Partners on its investment from GHO Capital; BGB Group on its investment from TPG; Clayton, Dubilier & Rice on its acquisition of UDG Healthcare; Fingerpaint on its acquisition of Splice; closerlook on its sale to Fishawack Health; Fingerpaint on its investment from Knox Lane; Clayton, Dubilier & Rice on its acquisition of Huntsworth (NKA Inizio); Court Square on its acquisition of Medical Knowledge Group; and W2O (NKA Real Chemistry) on its sale to New Mountain Capital.
Prior to joining Houlihan Lokey, Mr. Bleakley worked at Mizuho Securities, providing cross-border M&A advisory in the oil and gas and power and utilities sectors. Before that, he worked in the Transaction Advisory Services group at EY, providing valuation and business modeling services.
Mr. Bleakley earned an undergraduate degree in Applied Mathematics, with a second major in Finance, from the College of William & Mary.